Economic evaluation of AbobotulinumtoxinA vs OnabotulinumtoxinA in real-life clinical management of cervical dystonia

Table 4 Cost^a of treatment by treatment group

	AboBoNT-A LS Mean (95% CI)	OnaBoNT-A LS Mean (95% CI)	Difference^b (95% CI)
Unadjusted Model	310.31 (294.83, 325.78)	355.87 (331.61, 380.13)	−45.57 (−74.35, − 16.79)
Adjusted Model^c	314.07 (299.1, 329.03)	346.63 (322.85, 370.42)	−32.57 (− 61.04, − 4.09)

^aCost was calculated based on retail drug cost in euros
^bDifference was calculated as: mean of aboBoNT-A minus mean of onaBoNT-A
^cModel adjusted for sex, prior treatment with botulinum neurotoxin type A and electromyography (EMG) at baseline
aboBoNT-A abobotulinumtoxinA; onaBoNT-A onabotulinumtoxinA; LS Least-Square; CI Confidence Interval

ISSN: 2054-7072